Skip to main content
Regeneron, Sanofi's skin cancer drug gains breakthrough therapy status

Regeneron and Sanofi's fast track-designated REGN2810, or cemiplimab, for adult patients with metastatic and locally and unresectable advanced cutaneous squamous cell carcinoma was granted breakthrough therapy designation by the FDA. An early-stage trial demonstrated a 46% overall response rate and a 69% disease control rate with the drug.

Full Story: